Biotech ETF (IBB) Sinks Further as House Democrats Seek to Subpoena Valeant (VRX) on Drug Prices

iShares Nasdaq Biotechnology (NASDAQ: IBB) is moving to the lows following headlines the House oversight committee Democrats request subpoena for Valeant Pharma (NYSE: VRX), according to Bloomberg.

This likely has to do with the "price gouging" claim recently made by Presidential hopeful Hillary Clinton.

IBB is down 5.5% to $293.16.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• BofA says there is a continued strength in buybacks
• Gain Therapeutics (GANX) Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287